Sanofi: Analysts’ Recommendations on October 30



Analysts’ estimates

Wall Street analysts expect Sanofi’s (SNY) third-quarter revenues to increase 3.3% to 9.3 billion euros. The company’s EPS is estimated to be 1.71 euros for the third quarter.

The above chart shows analysts’ recommendations for Sanofi stock over the last 12 months.

Article continues below advertisement

Analysts’ ratings

Sanofi’s stock price has decreased nearly 11.0% over the last 12 months. The stock price has decreased ~1.7% in 2018 year-to-date. Analysts’ estimates show that the stock could return ~15.1% over the next 12 months. Analysts’ recommendations show a 12-month target price of $48.67 per share—compared to the last price of $42.29 per share as of October 29.

Analysts’ recommendations

As of October 30, four analysts are tracking Sanofi. Two analysts recommend a “strong buy,” while two analysts recommend a “hold.” The consensus rating for Sanofi is 2.0, which represents a “strong buy” for long-term investors.

Also, 24 analysts are tracking Sanofi stock listed on Euronext Paris. Six analysts recommend a “strong buy,” six analysts recommend a “buy,” 11 analysts recommend a “hold,” and one analyst recommends a “sell.” The changes in analysts’ estimates and recommendations are based on the changing trends in the stock price and Sanofi’s performance. The consensus rating for Sanofi stock stands at 2.29, which represents a moderate “buy” for value investors.

Sanofi’s valuations

As of October 30, Sanofi trades at a forward PE multiple of 12.5x—compared to the industry’s average of 15.2x. Sanofi trades at a forward EV-to-EBITDA multiple of 10.6x—compared to the industry’s average of 12.4x. Sanofi trades at a forward EV-to-revenues multiple of 3.1x—compared to the industry’s average of 4.6x.

Notably, the First Trust Value Line Dividend ETF (FVD) holds 0.5% of its total investments in Sanofi, 0.5% in Eli Lilly (LLY), 0.5% in Amgen (AMGN), and 0.5% in Medtronic (MDT).


More From Market Realist